Briacell Therapeutics
BCTX
17 hedge funds and large institutions have $19.4M invested in Briacell Therapeutics in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 5 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
58% more capital invested
Capital invested by funds: $12.3M → $19.4M (+$7.08M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% less ownership
Funds ownership: 0.11% → 0.11% (-0%)
6% less funds holding
Funds holding: 18 → 17 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$1.45M |
| 2 |
Morgan Stanley
New York
|
+$462K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$212K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$102K |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
+$99.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KJHP
K.J. Harrison & Partners
Toronto,
Ontario, Canada
|
-$2.22M |
| 2 |
Simplex Trading
Chicago,
Illinois
|
-$193K |
| 3 |
VF
Virtu Financial
New York
|
-$89K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$60.2K |
| 5 |
N
Natixis
Paris,
France
|
-$56.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$1K | -1 | Closed |
|
BCTX Hedge Fund Activity: Q1 2023 in Review
17 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Briacell Therapeutics (BCTX) for Q1 2023, worth a combined $19.4M — up 58% from $12.3M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of BCTX and 4 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 5 added.
The largest buyer was Wasatch Advisors, adding an estimated $1.45M. The largest seller was K.J. Harrison & Partners, cutting an estimated $2.22M.
- 17 institutional investors held Briacell Therapeutics (BCTX) as of Q1 2023, down from 18 in Q4 2022.
- Funds reported $19.4M of Briacell Therapeutics stock for Q1 2023, up 58% quarter-over-quarter.
- 4 funds opened new Briacell Therapeutics positions in Q1 2023 and 5 closed out, a net change of -1 holder.
- The largest Briacell Therapeutics buyer in Q1 2023 was Wasatch Advisors, an estimated $1.45M added.
- The largest Briacell Therapeutics seller in Q1 2023 was K.J. Harrison & Partners, an estimated $2.22M sold.
Based on aggregated 13F filings for Q1 2023.